Tags

Type your tag names separated by a space and hit enter

Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
Cancer Causes Control. 2019 May; 30(5):417-424.CC

Abstract

PURPOSE

This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2- breast cancer subtypes.

METHODS

Cases of first primary female invasive TP and ER+/PR+/HER2- breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2- subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2-.

RESULTS

The odds of TP versus ER+/PR+/HER2- were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40-1.55), black (OR 1.11; CI 1.02-1.21), Asian/Pacific Islander (OR 1.15; CI 1.09-1.22), and uninsured (OR 1.42; CI 1.15-1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2- subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2- subtype.

CONCLUSIONS

Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2- subtype. However the risk of mortality between these two subtypes is similar.

Authors+Show Affiliations

Sutter Institute for Medical Research, 2801 Capitol Ave, Suite 400, Sacramento, CA, 95816, USA. parisec@sutterhealth.org.Sutter Institute for Medical Research, 2801 Capitol Ave, Suite 400, Sacramento, CA, 95816, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30879205

Citation

Parise, Carol A., and Vincent Caggiano. "Differences in Clinicopatholgic Characteristics and Risk of Mortality Between the Triple Positive and ER+/PR+/HER2- Breast Cancer Subtypes." Cancer Causes & Control : CCC, vol. 30, no. 5, 2019, pp. 417-424.
Parise CA, Caggiano V. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes. Cancer Causes Control. 2019;30(5):417-424.
Parise, C. A., & Caggiano, V. (2019). Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes. Cancer Causes & Control : CCC, 30(5), 417-424. https://doi.org/10.1007/s10552-019-01152-8
Parise CA, Caggiano V. Differences in Clinicopatholgic Characteristics and Risk of Mortality Between the Triple Positive and ER+/PR+/HER2- Breast Cancer Subtypes. Cancer Causes Control. 2019;30(5):417-424. PubMed PMID: 30879205.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes. AU - Parise,Carol A, AU - Caggiano,Vincent, Y1 - 2019/03/16/ PY - 2018/10/08/received PY - 2019/02/22/accepted PY - 2019/3/18/pubmed PY - 2019/6/4/medline PY - 2019/3/18/entrez KW - Breast cancer KW - Luminal B KW - Mortality KW - Population-based registry KW - Risk factors KW - Triple positive SP - 417 EP - 424 JF - Cancer causes & control : CCC JO - Cancer Causes Control VL - 30 IS - 5 N2 - PURPOSE: This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2- breast cancer subtypes. METHODS: Cases of first primary female invasive TP and ER+/PR+/HER2- breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2- subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2-. RESULTS: The odds of TP versus ER+/PR+/HER2- were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40-1.55), black (OR 1.11; CI 1.02-1.21), Asian/Pacific Islander (OR 1.15; CI 1.09-1.22), and uninsured (OR 1.42; CI 1.15-1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2- subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2- subtype. CONCLUSIONS: Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2- subtype. However the risk of mortality between these two subtypes is similar. SN - 1573-7225 UR - https://www.unboundmedicine.com/medline/citation/30879205/Differences_in_clinicopatholgic_characteristics_and_risk_of_mortality_between_the_triple_positive_and_ER+/PR+/HER2__breast_cancer_subtypes_ L2 - https://doi.org/10.1007/s10552-019-01152-8 DB - PRIME DP - Unbound Medicine ER -